JACQUELINE BARRIOS

Ms. JACQUELINE BARRIOS


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
DNDaniel Nunez-Avellaneda
Daniel Nunez-Avellaneda
CTChandra S Tangudu
Chandra S Tangudu
JBJACQUELINE BARRIOS
JACQUELINE BARRIOS
MSMa Isabel Salazar
Ma Isabel Salazar
CMCarlos Machain-Williams
Carlos Machain-Williams
BBBrad Blitvich
Brad Blitvich
: The local public health authorities reported nine cases of chikungunya in Mexico in 2019, none of which occurred in Guerrero, a coastal state in the southwest. To test the hypothesis that chikungunya is grossly underreported in Mexico, acute sera were collected from 639 febrile patients from low-income households in Guerrero in 2019 and serologically assayed for chikungunya virus (CHIKV). Analysis of the sera by plaque reduction neutralization test revealed that 181 (28.3%) patients were seropositive for CHIKV. To identify patients with acute CHIKV infections, a subset of serum samples were tested for CHIKV-specific IgM by ELISA. Serum samples from 21 of 189 (11.1%) patients were positive. These patients met the chikungunya case definition established by the WHO. In conclusion, we provide evidence that CHIKV remains an important public health problem in Mexico and that the true number of cases is severely underestimated.

31 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
JBJACQUELINE BARRIOS
JACQUELINE BARRIOS
JBJorge Alberto Barrios-Payán
Jorge Alberto Barrios-Payán
DMDulce Mata-Espinosa
Dulce Mata-Espinosa
Jacqueline Lara EspinosaJacqueline Lara Espinosa
Jacqueline Lara Espinosa
JUAN CARLOS LEON CONTRERASJUAN CARLOS LEON CONTRERAS
JUAN CARLOS LEON CONTRERAS
Rogelio Hernández-PandoRogelio Hernández-Pando
Rogelio Hernández-Pando
Tuberculosis (TB) is considered the oldest pandemic in human history. The emergence of multidrug-resistant (MDR) strains is currently considered a serious global health problem. As components of the innate immune response, antimicrobial peptides (AMPs) such as cathelicidins have been proposed to have efficacious antimicrobial activity against Mycobacterium tuberculosis (Mtb). In this work, we assessed a cathelicidin from water buffalo, Bubalus bubalis, (WBCATH), determining in vitro its antitubercular activity (MIC), cytotoxicity and the peptide effect on bacillary loads and cytokines production in infected alveolar macrophages. Our results showed that WBCATH has microbicidal activity against drug-sensitive and MDR Mtb, induces structural mycobacterial damage demonstrated by electron microscopy, improves Mtb killing and induces the production of protective cytokines by murine macrophages. Furthermore, in vivo WBCATH showed decreased bacterial loads in a model of progressive pulmonary TB in BALB/c mice infected with drug-sensitive or MDR mycobacteria. In addition, a synergistic therapeutic effect was observed when first-line antibiotics were administered with WBCATH. These results were supported by computational modeling of the potential effects of WBCATH on the cellular membrane of Mtb. Thus, this water buffalo-derived cathelicidin could be a promising adjuvant therapy for current anti-TB drugs by enhancing a protective immune response and potentially reducing antibiotic treatment duration.

24 January 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
DNDaniel Nuñez
Daniel Nuñez
FVFabian R. Villagómez
Fabian R. Villagómez
JVJulio César Villegas-Pineda
Julio César Villegas-Pineda
JBJACQUELINE BARRIOS
JACQUELINE BARRIOS
MSMa Isabel Salazar
Ma Isabel Salazar
BBBrad Blitvich
Brad Blitvich
: We provide evidence of concurrent and close sequential infections between SARS-CoV-2 and select arboviruses—namely, chikungunya virus (CHIKV); dengue viruses 1, 2, and 3 (DENV1–3), and Zika virus (ZIKV)—in patients in Guerrero, southwest Mexico, in 2020–2021. The study population consisted of 176 febrile patients with laboratory evidence of SARS-CoV-2 infection. Sera from all patients were serologically and antigenically tested for seven arboviruses known to occur in Guerrero. Eighteen patients contained CHIKV IgM, six of whom also contained CHIKV RNA. Another 16 patients contained flavivirus antigen. The flaviviruses responsible for the infections were identified by plaque reduction neutralization test as DENV1 (two patients), DENV2 (five patients), DENV3 (three patients), ZIKV (three patients), and an undetermined flavivirus (three patients). In summary, we identified patients in Guerrero, Mexico, with concurrent or recent sequential infections between SARS-CoV-2 and select arboviruses, exemplifying the importance of performing differential diagnosis in regions where these viruses cocirculate.